-
Cannabis-based Therapy for Progressive MS Requests FDA ‘Fast Track’
The FDA has been asked to award MMJ-001, a cannabis-based treatment for primary progressive MS, “fast track” status in advanced of a planned clinical trial. Learn more about this story here.
The FDA’s fast track expedites the review and approval of experimental treatments for serious or life-threatening diseases with the potential to fill patients’ unmet medical needs. Do you think MMJ-001 fits the bill? What other therapies would you like to see get “fast tracked”?
Sorry, there were no replies found.
Log in to reply.